Recent advancements in the treatment of idiopathic multicentric Castleman disease (iMCD) have pointed to the efficacy of sirolimus, an mTOR inhibitor, particularly in cases that have not responded to traditional IL-6 inhibitors [35]. The gene discussed is IL6; the disease is idiopathic multicentric Castleman disease.